Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $45.95 Million

Brokerages expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $45.95 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $38.80 million and the highest is $56.70 million. Alnylam Pharmaceuticals reported sales of $29.91 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 53.6%. The firm is expected to announce its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $186.06 million for the current year, with estimates ranging from $113.10 million to $236.00 million. For the next fiscal year, analysts expect that the firm will post sales of $422.33 million, with estimates ranging from $321.46 million to $514.80 million. Zacks’ sales averages are an average based on a survey of analysts that follow Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. During the same quarter in the prior year, the business earned ($1.22) EPS. Alnylam Pharmaceuticals’s revenue was up 52.0% on a year-over-year basis.

Several brokerages have weighed in on ALNY. Evercore ISI upgraded Alnylam Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Wednesday, March 6th. BidaskClub downgraded Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Morgan Stanley upgraded Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target on the stock in a report on Tuesday, March 5th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $127.44.

Shares of NASDAQ ALNY opened at $70.80 on Friday. The company has a current ratio of 9.33, a quick ratio of 9.12 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 1-year low of $60.27 and a 1-year high of $124.21. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of -9.35 and a beta of 2.59.

In other news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the transaction, the director now owns 250,633 shares in the company, valued at approximately $22,113,349.59. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Maraganore sold 49,457 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total value of $3,461,990.00. Following the completion of the transaction, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC grew its stake in Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 987,770 shares of the biopharmaceutical company’s stock worth $92,307,000 after buying an additional 33,174 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,557 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 221 shares during the last quarter. FMR LLC grew its stake in Alnylam Pharmaceuticals by 5.2% during the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock worth $1,490,122,000 after buying an additional 791,113 shares during the last quarter. Maverick Capital Ltd. grew its stake in Alnylam Pharmaceuticals by 14.5% during the 1st quarter. Maverick Capital Ltd. now owns 3,210,387 shares of the biopharmaceutical company’s stock worth $300,011,000 after buying an additional 406,436 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in Alnylam Pharmaceuticals by 318.0% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 62,700 shares of the biopharmaceutical company’s stock worth $5,860,000 after buying an additional 47,700 shares during the last quarter. Institutional investors and hedge funds own 89.78% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: What does it mean to hold a stock in street name?

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.